Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02903381
Recruitment Status : Suspended (FDA Partial Clinical Hold)
First Posted : September 16, 2016
Last Update Posted : July 21, 2020
Sponsor:
Collaborators:
Bristol-Myers Squibb
Multiple Myeloma Research Consortium
Blood Cancer Research Partnership
Information provided by (Responsible Party):
Irene Ghobrial, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : February 2024